• OPEN AN ACCOUNT
Indian Indices
Nifty
25,423.60 93.35
(0.37%)
Sensex
83,013.96 320.25
( 0.39%)
Bank Nifty
55,727.45 234.15
( 0.42%)
Nifty IT
36,750.25 303.10
( 0.83%)
Global Indices
Nasdaq
46,015.42 236.51
(0.52%)
Dow Jones
6,617.88 9.88
(-0.15%)
Hang Seng
45,342.39 552.01
(1.23%)
Nikkei 225
9,208.37 12.71
(0.14%)
Forex
USD-INR
88.02 0.00
(0.00%)
EUR-INR
104.02 0.00
(0.00%)
GBP-INR
120.02 0.00
(0.00%)
JPY-INR
0.60 0.00
(0.00%)

EQUITY - MARKET SCREENER

Divis Laboratories Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value()
532488
INE361B01024
561.0868795
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
DIVISLAB
68.76
160625.75
EPS(TTM)
Face Value()
Div & Yield %
88
2
0.49
 

Divis Lab gains as broker reiterates buy call
Aug 22,2025
The brokerage downplayed concerns over Eli Lilly’s oral GLP-1 candidate Orforglipron and generic risks to Novartis’ heart drug Entresto, which contributes about 20% of Divi’s consolidated revenue. It expects Divi’s to remain a key API supplier, supported by a healthy order pipeline and rising demand in peptides, making the recent stock weakness a buying opportunity.

Over the past month, the stock has fallen 7.08% compared with a 0.84% decline in the Sensex.

Divis Laboratories is engaged in the manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. The company's consolidated net profit rose 26.74% to Rs 545 crore while net sales rose 13.79% to Rs 2410 crore in Q1 June 2025 over Q1 June 2024.